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and Nai Ki Mak1,7*Abstract
Background: Nasopharyngeal carcinoma (NPC) is an epithelial malignancy strongly associated with Epstein-Barr
virus (EBV). AT13387 is a novel heat shock protein 90 (Hsp90) inhibitor, which inhibits the chaperone function of
Hsp90 and reduces expression of Hsp90-dependent client oncoproteins. This study aimed to evaluate both the
in vitro and in vivo antitumor effects of AT13387 in the EBV-positive NPC cell line C666-1.
Results: Our results showed that AT13387 inhibited C666-1 cell growth and induced cellular senescence with the
downregulation of multiple Hsp90 client oncoproteins EGFR, AKT, CDK4, and restored the protein expression of
negative cell cycle regulator p27. We also studied the ability of AT13387 to restore p27 expression by downregulation
of AKT and the p27 ubiquitin mediator, Skp2, using AKT inhibitor and Skp2 siRNA. In the functional study, AT13387
inhibited cell migration with downregulation of a cell migration regulator, HDAC6, and increased the acetylation and
stabilization of α-tubulin. We also examined the effect of AT13387 on putative cancer stem cells (CSC) by 3-D tumor
sphere formation assay. AT13387 effectively reduced both the number and size of C666-1 tumor spheres with
decreased expression of NPC CSC-like markers CD44 and SOX2. In the in vivo study, AT13387 significantly suppressed
tumor formation in C666-1 NPC xenografts.
Conclusion: AT13387 suppressed cell growth, cell migration, tumor sphere formation and induced cellular senescence
on EBV-positive NPC cell line C666-1. Also, the antitumor effect of AT13387 was demonstrated in an in vivo model. This
study provided experimental evidence for the preclinical value of using AT13387 as an effective antitumor agent in
treatment of NPC.
Keywords: AT13387, Hsp90 inhibitor, Senescence, Antitumor, Nasopharyngeal carcinomaBackground
Nasopharyngeal carcinoma (NPC) is a malignancy aris-
ing from the epithelial cells of the nasopharynx. It has a
distinct geographic distribution with a remarkably high
disease incidence in southern China and Southeast Asia
with more than 50,000 new cases each year [1]. Appar-
ently, all NPC is associated with the Epstein-Barr virus
(EBV) latent infection, indicating the role of EBV in* Correspondence: nkmak@hkbu.edu.hk
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reproduction in any medium, provided the orNPC pathogenesis [2]. However, most of the NPC cell
lines had lost the EBV genome after a long time in vitro
passage. C666-1 is the NPC cell line consistently main-
taining the native EBV genome and referred as a suitable
model for studies of EBV-associated NPC [3]. Nowadays,
combined radiotherapy and chemotherapy are used for
the treatment of NPC patients [4,5]. Most contemporary
series reported very encouraging results with locoregio-
nal control exceeding 90%, but distant failure remains
high and more potent systemic therapy is needed.
Heat shock protein 90 (Hsp90) is a molecular chaperone
involved in the maturation and stabilization of over 200
oncogenic client proteins crucial for oncogenesis [6-8].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.molecular-cancer.com/content/12/1/128Hsp90 inhibitors exert the antitumor effect by blocking
the ATP binding domain of Hsp90 to abolish the Hsp90
chaperone function and leading to proteasomal degrad-
ation of the oncogenic client proteins. In tumor cells, the
dependency of oncoproteins on the chaperone function of
Hsp90 is much higher than in normal cells, and the bind-
ing affinity of Hsp90 inhibitor to Hsp90 was 100-fold
higher in tumor cells than in normal cells [9-11]. For this
reason, inhibition of the Hsp90 machinery is considered
as a potent strategy in cancer therapies [12].
AT13387 is a small-molecule inhibitor of Hsp90 devel-
oped by Astex Pharmaceuticals Inc through fragment-
based drug screening against the ATP-binding domain
of Hsp90 [13]. Several studies also reported AT13387 as
an effective antitumor agent in both the in vitro and
in vivo cancer models, such as gastrointestinal stromal
tumor (GIST) and non-small cell lung cancer (NSCLC)
[14,15]. AT13387 clinical activity against GIST was dem-
onstrated in the Phase I and Phase II trials (ClinicalTrials.
gov Identifier: NCT00878423 [16] and NCT01294202
[17], respectively), and further clinical trials in prostate
(NCT01685268) and lung cancer (NCT01712217) in com-
bination with standard of care are ongoing.
In NPC, many of the aberrantly overexpressed onco-
proteins such as EGFR, AKT, and CDK4 are known
Hsp90 client proteins [12,18,19]. We hypothesize that
targeting the chaperone function of Hsp90 in NPC cells
can lead to downregulation of multiple crucial oncopro-
teins and regression of tumor. Therefore, we aim to
study the tumor suppressive efficacy of AT13387 in the
C666-1 EBV-positive NPC cell line and provide preclin-
ical evidence of using AT13387 as a novel antitumor
agent in treatment of NPC.
Results
Growth inhibitory effect of AT13387 on the EBV-positive
NPC cell line C666-1
The growth inhibitory effect of AT13387 on the EBV-
positive NPC cell line C666-1 was demonstrated in the
MTT assay (Figure 1A) and cell growth assay (Figure 1B).
In MTT assay, C666-1 was treated with various con-
centrations of AT13387 for 48 hours. Results showed
that AT13387 inhibited the growth of C666-1 dose-
dependently when compared with untreated control.
Maximum inhibition of cell growth was observed in
C666-1 treated with 1 μM to 10 μM AT13387. There-
fore, 1 μM and 10 μM AT13387 were chosen for further
analysis. In the cell growth assay, number of viable
C666-1 cells after 1 μM and 10 μM AT13387 treatment
for 2 to 7 days were determined by cell counting. The
total number of AT13387-treated C666-1 cells at day-2,
4, and 7 was similar to the initial number of C666-1
cells at day 0, showing no growth of AT13387-treated
C666-1 cells, while the control cells continued to growtill Day 4 after which it reached a plateau. The total
number of AT13387-treated C666-1 cells at day-2, 4,
and 7 was significantly lower than their respective control
groups (*p < 0.05). Next, we tried to determine whether
the mode of growth inhibition of AT13387 on C666-1
cells was due to induction of apoptosis. However, DNA
content analysis of 1 μM and 10 μM AT13387-treated
C666-1 showed no clear increase of sub-G1 peak after
48 hours (Figure 1C) and DAPI nuclei staining of
AT13387-treated C666-1 did not reveal the typical appear-
ance of apoptotic cells with chromatin condensation and
fragmentation (Figure 1D). Results showed no apparent
apoptotic phenotype in the AT13387-treated C666-1 cells.
In addition to the nuclear staining and DNA content ana-
lysis, the expression of pro-apoptotic proteins (cleaved
form of Caspase-3 and BAX) and anti-apoptotic proteins
(Bcl-2 and Bcl-xl) were analysed (Figure 1E). The Western
blotting result showed after 48 hours and 96 hours of
AT13387 treatment, cleaved forms of caspase-3 (19 kDa
and 17 kDa) and BAX pro-apoptotic proteins were not
expressed in AT13387-treated C666-1. The expression of
anti-apoptotic proteins Bcl-2 and Bcl-xl in AT13387-
treated C666-1was also not decreased, indicating that
induction of apoptosis is not the major mechanism in
AT13387-treated C666-1 cells.
AT13387 induces senescence in C666-1
Cellular senescence is a permanent and irreversible
process in the induction of cell growth arrest without
induction of massive cell death [20,21]. Chemotherapy-
induced senescence is one of the tumor suppression
mechanisms in antitumor therapy. Since an apoptotic
response was not observed in the C666-1 cells in the
mentioned AT13387 experiments, we sought to deter-
mine whether the growth inhibitory effect of AT13387
was due to the induction of cellular senescence. C666-1
cells treated with AT13387 for 72 hours were then
stained for the senescence-associated β-galactosidase
(SA-β-gal). Results in Figure 2A showed that SA-β-
gal-positive cells stained in blue were observed in cells
after AT13387 treatment. Since the blue staining of SA-
β-gal is weakly expressed and difficult to quantify, the for-
mation of senescence-associated heterochromatin foci
(SAHF) [22], was then performed. Compact punctuate
DAPI-stained SAHF were clearly seen and quantified in
AT13387-treated C666-1 cells after 96 hours (*p < 0.05)
(Figure 2B). Results from this study indicated that
AT13387 induced cellular senescence in the C666-1 cells.
Western-blotting analysis of senescence and growth
associated Hsp90 client oncoproteins and the re-expression
of p27 after AT13387 treatment
Induction of cellular senescence is usually associated
with the altered expression of cell cycle regulators. We
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Figure 1 Effect of AT13387 on EBV-positive NPC cell line C666-1. (A) MTT assay showing dose dependent inhibition of C666-1 cells growth
after 48 hrs of AT13387 treatment. (B) Cell growth assay showing the kinetics of growth inhibition determined by counting number of viable
C666-1 cells on days 2, 4 and 7 after AT13387 treatment. Results are expressed as the mean ± S.D. of three separate trials; *p < 0.05. (C) DNA
content analysis and (D) DAPI nuclei staining showed no significant apoptotic phenotype in AT13387-treated C666-1 after 48 hrs. Arrow indicated
the sub-G1 peak of DNA profile. Scale bar = 20 μm. (E) Western-blotting analysis showing no significant change of pro-apoptotic and anti-apoptotic
proteins in AT13387-treated C666-1 after 48 hrs and 96 hrs. Value represented the arbitrary unit of band intensity after normalization with β-actin.
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associated Hsp90 client proteins CDK2 and CDK4 in
AT13387-treated C666-1 cells. At the concentration of
1 μM (72 hours), the expression level of CDK2 and
CDK4 was about 88% and 35% of the control value,
respectively (Figure 3A). At the concentration of 10 μM,
the protein expression level of CDK2 (96 hours) was
about 40% of the control group, indicating that AT13387
exerted a greater inhibitor effect on the expression of
CDK4 than the CDK2. Rb protein is the downstream
target of CDK2 and CDK4, and the state of Rb phos-
phorylation is known to regulate the cell growth and
cellular senescence. Furthermore, the activity of CDK2
and CDK4 is regulated by the cell cycle regulators p16,
p21, and p27. We then measured the expression of p16,
p21, p27 and the phosphorylated form of Rb protein
(p-Rb, inactive form) in AT13387-treated C666-1. Al-
though the upregulated expression of p16 is generally
considered as a major effector in the induction of senes-
cence, p16 was not expressed by both untreated and
AT13387-treated C666-1 cells. This can be explained by
the fact that the CDKN2A-CDKN2B gene cluster on 9p21
encoding p16 is a highly susceptible loci in NPC [23], so
that the re-expression of p16 is not observed in the
commonly deleted loci in C666-1. Meanwhile, the expres-
sion level of important senescence regulators p21 and p27
was increased in cells after AT13387 treatment. At the
concentration of 10 μM, there was about a 1.62 and 2.75-
fold increase in the expression of p21 and p27, respect-
ively at 72 hours after AT13387 treatment, and the
increase in p21 and p27 expression were also accompan-
ied by a decrease in the expression of p-RB. However, the
reduction in the level of p-RB was not apparent at 96 hours
after the treatment. Taken together, upregulation of p21
and p27 was well correlated with the downregulation of
CDK4 in AT13387-treated C666-1 cells.
The negative cell cycle regulator p27 has previously
been reported as a commonly downregulated tumor
suppressive protein in NPC. In order to further study
the mechanism of resotration of p27 protein expression
in AT13387-treated C666-1 cells, we first measured the
p27 mRNA expression by real-time quantitative PCR.
However, the p27 mRNA level was unchanged by
72 hours treatment with AT13387 (data not shown),
then we focused on the regulation of p27 at the protein
level. The degradation of p27 protein is known torequire the interaction between p27 and the F-box pro-
tein S-phase kinase 2 (Skp2) in the SCFskp2 complex
[24]. Since p27 is a normal physiological target of Skp2
for ubiquitination, we then studied the inversed expres-
sion of Skp2 and p27 by treating C666-1 cells with Skp2
siRNA. Results in Figure 3B showed that the expression
of p27 proteins was increased in the Skp2 siRNA-treated
C666-1. It has previously been shown that Skp2 is highly
expressed in NPC tumor with poor prognosis [25,26],
and the stability of Skp2 is regulated by AKT [27]. We
then measured the protein expression of Skp2 after add-
ing the AKT inhibitor SH-6 in C666-1. Results in
Figure 3C showed with the downregulation of p-AKT,
the Skp2 is coordinately downregulated in SH-6 treated
C666-1. We then further determined the expression of
Skp2 and AKT in AT13387-treated C666-1 cells.
Figure 3D showed that the expression of Skp2, AKT, and
phosphorylated form of AKT (p-AKT) were all reduced
in the AT13387-treated C666-1 cells. This observation
suggested that the ability of AT13387 to restore p27
protein expression may due to downregulation of p27
ubiquitination mediator Skp2 through downregulating
AKT and p-AKT.
Apart from AKT, EGFR is one of the most commonly
overexpressed oncoproteins in NPC [18,19]. Targeting
EGFR has been suggested as a new therapeutic treat-
ment in NPC and EGFR is also a known Hsp90 client
oncoprotein. In this study, AT13387 significantly re-
duced EGFR and its downstream target p-STAT3 in
C666-1 (Figure 3D). It is worthy to note that AT13387 is
designed to block the Hsp90 chaperon function, there-
fore the expression level of Hsp90 was not affected by
AT13387. Taken together with the downregulation of
CDK4, AKT, and Skp2, AT13387 can deplete multiple
oncoproteins and restore the tumor suppressive protein
p27 in EBV-positive NPC cell line. This result sup-
ported the potential use of AT13387 as an antitumor
agent in NPC by simultaneously targeting multiple NPC
oncoproteins.
Inhibition of tumor cell migration
Tumor cell metastasis is one of the current problems in
the treatment of NPC, the migration capability of
AT13387-treated C666-1 cells was then evaluated using
a transwell migration assay. The C666-1 cells pre-treated
with AT13387 for 72 hours were harvested and seeded
AB
Figure 2 Characterization of senescence phenotypes in AT13387-treated C666-1. (A) Staining of senescence-associated β-galactosidase (SA-
β-gal). Senescent cells were identified as cells stained blue after 72 hrs of AT13387 treatment. Scale bar = 50 μm. (B) DAPI staining and quantification
of senescence-associated heterochromatic foci (SAHF). Upper panel: microscopic image showing formation of SAHF in C666-1 cells with AT13387
treatment for 96 hrs. Scale bar = 10 μm, red arrow indicated cells with typical SAHF. Lower panel: bar chart showing the percentage of cells with SAHF.
At least 200 cells were counted from different microscopic fields for each treatment. Results were expressed as the mean ± S.D. of three independent
experiments; *p < 0.05.
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http://www.molecular-cancer.com/content/12/1/128on the upper chamber of transwell for migration assay.
Cells migrated through the membrane of migration
chamber were stained with DAPI and at least 100 cells
per treatment were counted from different microscopic
fields. Figure 4A showed the migration capability of
AT13387-treated C666-1 cells was significantly reduced
(*p < 0.05). At the concentration of 1 μM and 10 μM,
the percentage of migrated cells was reduced to 8% and
5%, respectively, compared to the untreated control. Since
the assembly (acetylation of α-tubulin) and disassembly
(deacetylation of α-tubulin) of microtubule is important in
cell migration. Next, we determined the expression of aknown microtubule-associated deacetylase, histone deace-
tylase 6 (HDAC6), and the acetylation status of α-tubulin
in AT13387-treated C666-1 cells. HDAC6 is a cell migra-
tion regulator and it is also client protein of Hsp90
[28-30]. Results in Figure 4B showed that the expression
of HDAC6 was greatly diminished in cells after AT13387
treatment. The effect was accompanied with an increased
in the expression of acetylated form of the α-tubulin. This
finding suggested that the migration inhibitory activity of
AT13387 might be due to the disruption of the micro-
tubule dynamic through the reduction of the expression
of HDAC6.
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Figure 3 Western-blotting analysis of Hsp90 client proteins and F-box protein S-phase kinase 2 (Skp2) in AT13387-treated C666-1.
(A) Expression of senescence and cell cycle associated Hsp90 client proteins in C666-1 after 72 hrs and 96 hrs AT13387 treatment. (B) Knockdown
of Skp2 by siRNA leaded to upregulation of p27 in C666-1. (C) Downregulation of p-AKT (Ser473) and Skp2 by AKT inhibitor. (D) Downregulation
of Skp2 and Hsp90 client oncoproteins AKT, p-AKT (Ser473), EGFR, and p-STAT3 after AT13387 treatment. Value represented the arbitrary unit of
band intensity after normalization with β-actin.
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growth, accompanied by reduction of CD44 and
SOX2 expression
3-D tumor sphere formation assay is frequently used as
an in vitro assay to evaluate the clonogenicity of tumor
cells. This method is also frequently used to measure the
growth of putative cancer stem cells (CSCs) under the
serum-free and an ultra-low attachment conditions
[31-33]. In a recent EBV-associated NPC cancer stem-
like cells study, the CSC population in C666-1 tumor
spheres were found to have upregulation of multiple
stem cell markers and high tumor initiating ability in
nude mice. Both CD44 and SOX2 CSC-like markers
were overexpressed in the C666-1 tumor sphere and the
isolated CD44+ NPC cells were found to be more resist-
ant to chemotherapeutic agent [34]. In the present study
we further examined the inhibitory effect of AT13387 on
C666-1 tumor spheres. Total number of tumor spheres
having diameter >20 μm in each culture were counted
and compared. Figure 5A showed AT13387 completely
inhibited the formation of C666-1 tumor spheres. The
C666-1 cells treated with AT13387 remained as single
cell while tumor spheres were formed in the untreated
culture in 7 days. Next, we further studied the inhibitory
effect of AT13387 on the growth of established tumor
spheres. AT13387 was added on day-7 after the initiation
of tumor sphere formation assay. Results in Figure 5B
showed the representative images and size profiles of
untreated tumor spheres and tumor spheres after
AT13387 treatment for another 7 days. The mean diam-
eter of control tumor spheres was 56 μm while the mean
diameter of 1 μM and 10 μM AT13387-treated tumor
spheres were 22 μm and 28 μm, respectively. The
AT13387-treated tumor spheres were significantly
smaller than the untreated control (p < 0.05), showing
the inhibitory effect of AT13387 on the growth of C666-1
tumor sphere. We then studied the effect of AT13387 on
CD44 and SOX2 in C666-1 tumor spheres. Figure 5C
showed the confocal image of CD44 (green)-and SOX2
(red)-stained tumor spheres. Highly reduced expression of
CD44 was observed in 1 μM AT13387-treated tumor
sphere and loss of both CD44 and SOX2 were observed in
10 μM AT13387-treated tumor sphere. We further quan-
tified the reduction of CD44 and SOX2 expression by
Fluorescence-activated Cell Sorting (FACS) analysis. In
Figure 5D, the upper panel showed the dot-plot of
CD44 and SOX2 stained cells. The CD44hi and SOX2hipopulations were indicated by red squares and quanti-
fied in a bar chart presented in the lower panel. Result
showed there was a 3-fold reduction of CD44hi and
SOX2hi populations in 1 μM and 10 μM AT13387-
treated C666-1 tumor spheres compared with the un-
treated control tumor spheres (*p < 0.05). Both the
immunofluorescence staining and FACS analysis showed
AT13387 significantly reduced the CD44 and SOX2 ex-
pression in C666-1 tumor spheres.
AT13387 suppressed NPC tumor formation in nude
mouse tumorigenicity assay
The antitumor effect of AT13387 in vivo was studied
using the nude mouse tumorigenicity assay. The nude
mice were subcutaneously injected with 1×107 C666-1
cells. After cell inoculation, the mice were randomly di-
vided into two groups to receive either 50 mg/kg
AT13387 treatment or vehicle control through i.p. injec-
tion twice a week for a total of 4 weeks. The tumor vol-
ume and body weight of the mice were measured
weekly. Figure 6A showed that the average tumor
volume of the vehicle control group which reached
800 mm3 by week 3 and continued to grow and ex-
ceeded 1300 mm3 by week 4. For the AT13387 treat-
ment group, the average tumor volume reached 200 mm3
at week 3, but did not exceed 400 mm3 until week 4.
AT13387 significantly suppressed tumor formation in
nude mice (p = 0.02), with no adverse effect on mice
body weight (Figure 6B) and no apparent harmful ef-
fects, when compared to the control mice receiving
vehicle alone.
Discussion
Cancer is a complex disease, with multiple aberrantly
overexpressed oncogenic proteins involving activation of
multiple signaling pathways. The stability of most of
these oncoproteins depends heavily on the chaperon
function of Hsp90. For this reason, the molecular
chaperone Hsp90 is an attractive therapeutic target in
cancer therapy. In the present study, we demonstrated
both the in vitro and in vivo antitumor effects of a novel
Hsp90 inhibitor, AT13387, on C666-1 EBV-positive NPC
cells. First of all, AT13387 was found to inhibit cell
growth and induce cellular senescence in the C666-1
EBV-positive NPC cells. Inhibition of cell growth and
induction of cellular senescence, instead of induction of
cell death through Hsp90 inhibition has also been
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http://www.molecular-cancer.com/content/12/1/128reported in small cell lung cancer as a mode of cancer
cell response to Hsp90 inhibitor [35]. Cellular senes-
cence is a permanent and irreversible process in the
induction of cell growth arrest without massive cell
death [20,21]. The induction of cellular senescence has
recently been proposed as a novel approach to improve
cancer therapy with less severe side effects than cyto-
toxic therapies and high dose radiation [36,37].
In the present study, AT13387 was found to downreg-
ulate several cell growth and cellular senescence associ-
ated Hsp90 client oncoproteins, including CKD4, AKT
and EGFR. Also, we reported the correlation betweenrestoration of p27 protein expression and the downregu-
lation of S-phase kinase associated protein 2 (Skp2).
Skp2 is the F-box protein responsible for substrate rec-
ognition in the Skp1-Cullin1-F-box (SCF) E3 ubiquitin
ligase and specifically targeting the tumor suppressive
proteins such as p27 for ubiquitination and proteasomal
degradation [24]. The role of the Skp2 in the regulation
of cellular senescence has recently been reported [38]
and reviewed [39]. In the present study, we found that
AT13387 induced senescence in C666-1 cells and the
effect was correlated with the reduction of the Skp2 and
the increased expression of p27. The stability of Skp2
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image of tumor spheres formed from C666-1 single cell culture with and without AT13387 treatment. AT13387 significantly inhibited tumor
sphere formation. Scale bar = 100 μm. Lower panel: Total number of tumor spheres per culture. Tumor spheres formed with diameter reaching
20 μm were counted. Results were expressed as the mean ± S.D. of three experiments; *p < 0.05. (B) Size profile of C666-1 tumor spheres.
AT13387 was added to the tumor sphere culture after tumor spheres were formed for 7 days. The diameters of tumor spheres were measured
after AT13387 treatment for 7 more days and presented as the size profile of tumor sphere. The mean diameters of tumor spheres with AT13387
treatment were significantly smaller than the untreated control (p < 0.05), showing the inhibitory effect of AT13387 on the growth of C666-1
tumor sphere. Scale bar = 50 μm. Results were expressed as the mean ± S.D. of three experiments. (C) Confocal image showing pseudocolor
green for CD44 and red for SOX2. Loss of CD44 was observed in 1 μM AT13387-treated C666-1 tumor sphere and loss of both CD44 and SOX2
were observed in 10 μM AT13387-treated C666-1 tumor sphere. Scale bar = 20 μm. (D) FACS analysis showing the decrease of CD44hi and SOX2hi
population in AT13387-treated C666-1 tumor sphere. Results were expressed as the mean ± S.D. of three experiments; *p < 0.05.
Chan et al. Molecular Cancer 2013, 12:128 Page 9 of 15
http://www.molecular-cancer.com/content/12/1/128has been reported to be dependent on the phosphoryl-
ation by AKT [40]. We further demonstrated that the
loss of Skp2 was correlated with the reduced expression
of the Hsp90 client proteins AKT in the treated C666-1cells. These findings suggested that AT13387 inhibit cell
growth and induce cellular senescence in C666-1 by
downregulating cell growth and cellular senescence asso-
ciated Hsp90 client proteins and also restored the tumor
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Figure 6 AT13387 suppressed tumor formation in nude mouse tumorigenicity assay. (A) The tumor volume of AT13387-treated mice and
vehicle control mice (n = 3) were measured weekly. The solid line represented the average tumor volume of vehicle control group, which reached
1300 mm3 in week 4. The dashed line represents the average tumor volume of AT13387-treated mice which showed significant suppression of tumor
formation when compared to vehicle control. (B) The mouse body weight of AT13387-treated mice and control mice during the experiment. The
result showed no significant difference for mouse body weight after AT13387 drug treatment group when compared to control group.
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http://www.molecular-cancer.com/content/12/1/128suppressive protein p27 by downregulating Skp2 through
downregulation of Hsp90 client protein AKT and p-AKT.
The downregulation of Skp2 by AT13387 showed an
important clinical relevance in the treatment of NPC
which is worthy to discuss. Recent studies on the clinical
samples from Taiwan and South China showed that
Skp2 was overexpressed in 80% NPC tumor and the
expression was correlated with poor prognosis [25,26].
The overexpression of Skp2 in NPC clinical samples
may explain the commonly loss of p27 in NPC tissues
[41,42]. The oncogenic role of Skp2 in NPC pathogen-
esis has been studied in NPC cells transfected with Skp2
of showing higher colony forming ability and the side
population of NPC cells showed higher level of Skp2
[25,26]. However, up until now, no pharmacological
Skp2 inhibitor has yet been available for clinical use. In
our study, we demonstrated Skp2 can be downregulated
by AT13387 in C666-1. This observation suggested that
NPC patients with a high Skp2 expression might benefit
from AT13387 for personalized therapy.As mentioned above, AT13387 can target on multiple
oncoproteins simultaneously. We studied the depletion
of a very important NPC oncoprotein EGFR in AT13387-
treated C666-1. EGFR has been reported to be overex-
pressed in 85% of NPC tissues and the expression is
associated with poor prognosis [43]. EGFR is the recep-
tor tyrosine kinase of the natural ligand EGF and TGF.
Activation of EGFR was associated with proliferation,
migration, and drug resistance, which play an important
role in NPC pathogenesis. In recent years, EGFR has
been proposed as a new therapeutic target for NPC.
EGFR inhibitors such as cetuximab and gefitinib, which
are the monoclonal antibody and the small molecule
against EGFR, respectively, are currently under NPC
clinical evaluations [44]. However, targeting a single
oncoprotein is unlikely to be effective enough to elimin-
ate the disease, as the tumor cells may switch from
utilization of one signaling pathway to another signaling
pathway for growth [45]. Despite the promising effect of
EGFR inhibitors in the preclinical and clinical studies,
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ment in clinical studies [46,47]. In one third of gefitinib
non-responsive NPC patients, AKT was found to be
overexpressed [48]. The activation of AKT pathway in
gefitinib-resistant cells may take over the EGFR pathway
and therefore maintain the tumorigenicity and escape
from the EGFR targeted therapy. In the present study,
we observed the simultaneous downregulation of EGFR,
EGFR downstream signaling molecules p-STAT3, AKT
and p-AKT. Hence, targeting multiple oncoproteins
using AT13387 alone or in combination with specific an-
titumor agents may serve as a potential solution to over-
come the development of drug resistance in NPC
targeted therapy.
One of the current problems in the treatment of NPC
is the development of distant metastasis and tumor
recurrence. HDAC6, also a client protein of Hsp90 [29],
is a key modulator involved in the regulation of cell
migration through the deacetylation of tubulins in the
cytoplasm [28,30,49]. Overexpression of HDAC6 is fre-
quently correlated with the tumor development, and
hence HDAC6 is considered to be a target for cancer
therapy [50]. However, the role of HDAC6 in NPC has
not been demonstrated. In the present study, we found
that the expression of HDAC6 was downregulated by
AT13387. The effect was correlated with the increase in
the acetylation of α-tubulin and the decrease in the tumor
cell migration. This finding indicates that AT13387 may
reduce metastasis through the disruption of microtubules
dynamics.
In addition to the mechanistic study, two biological
end-point assays, namely the in vitro 3D tumor sphere
formation assay and the in vivo NPC xenograft, were
used to evaluate the efficacy of AT13387 for NPC. The
tumor sphere assay is frequently used to measure the
in vitro self-renewal capability of cancer stem cells and
to assess the effectiveness of the drug on the cells in the
presence of growth factors [31-33]. Our results clearly
showed that AT13387 not only reduced the in vivo
tumor formation, but also reduced the formation and
growth of NPC tumor spheres accompanied by reduced
expression of cancer stem-like cells markers CD44 and
SOX2. Lo KW and co-workers have recently demon-
strated that CD44 and SOX2 expression are enriched in
C666-1 tumor sphere forming cells which may serve as
the potential candidate stem cell markers for the NPC
C666-1 cells [34]. CD44 is a well known cell surface
marker involved in the signal transduction of multiple
oncogenic pathways [51-53]. SOX2 is a well known mas-
ter transcription factor of stem cells [54]. Decreased
expression of CD44 and SOX2 might reduce the onco-
genic potential of the tumor cells. The result revealed the
potential of AT13387 on targeting the CD44-and SOX2-
overexpressing NPC subpopulation. Taken together, resultsfrom the present study suggest that targeting on multiple
oncogenic pathways by AT13387 is a novel approach in
the treatment of NPC. Further development will focus on
the evaluation of using AT13387 as a single agent or in
combination with other current therapies in the treatment
of NPC.
Conclusion
Our study demonstrated the in vitro and in vivo antitu-
mor effect of a novel Hsp90 inhibitor, AT13387, on the
EBV-positive NPC cell line C666-1. AT13387 inhibited
cell growth, cell migration, tumor sphere formation and
induced cellular senescence in C666-1. The ability of
AT13387 to target multiple NPC oncoproteins, make it
a potent antitumor agent in treatment of NPC. Together
with the tumor suppressive effect of AT13387 in nude
mice tumorigenicity assay, this study provided preclin-
ical evidence of using AT13387 as a new therapeutic
agent in treatment of NPC.
Methods
Chemical and antibodies
AT13387 was synthesized and provided by Astex Phar-
maceuticals Inc [13]. AKT inhibitor SH-6 was purchased
from Calbiochem, San Diego, CA. Primary antibodies
for Western blotting analysis include Caspase-3, BAX,
Bcl-2, Bcl-xl, CDK2, CDK4, p16, p21, p27, Rb, STAT3,
p-STAT3 (Tyr705), AKT, p-AKT (Ser473), Skp2 (Cell
Signaling, Danvers, MA); EGFR, Hsp90, and HDAC6
(Santa Cruz Biotechnology, Santa Cruz, CA); and acety-
lated α-tubulin and β-tubulin (Sigma-Aldrich, St. Louis,
MO). Antibodies for immunofluorescence staining were
Alexa Fluor® 488 conjugated CD44 and Alex Fluor® 647
conjugated SOX2 (Cell Signaling, Danvers, MA).
Cell line and cell culture
C666-1, an EBV-positive NPC cell line still carrying the
native EBV genomes [3], were cultured in RPMI-1640
medium (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA)
and 1% penicillin and streptomycin (P/S) (Invitrogen,
Carlsbad, CA). Cells were cultured at 37°C with 5% CO2
in humidified incubator.
MTT cell viability assay
Viable cells treated with various dose of AT13387 were
measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay as previously de-
scribed [55]. Briefly, C666-1 (3×104) were seeded in
96-well microplates and treated with serial diluted
AT13387 (0.001 μM-10 μM) for 48 hours. MTT solution
(Sigma-Aldrich, St. Louis, MO) (0.25 mg⁄ml) was added
to cells and incubated for 3 hours in 37°C. The optical
densities (OD) were measured at absorbance 550 nm
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proportional to the number of living cells and the per-
centage of viable cells compared to control wells was
calculated.
Cell growth assay
The kinetic effect of AT13387 on proliferation of C666-1
was studied using a cell growth assay. C666-1 cells
(3×105) were seeded onto 35 mm culture dishes. The
cells were then treated with AT13387 (1 μM and 10 μM)
for 2 to 7 days. The total number of viable cells deter-
mined by trypan blue staining was counted on day 2, 4,
and 7 after AT13387 treatment.
DNA content analysis
DNA content analysis was performed using propidium
iodide (PI) staining and flow cytometry analysis as previ-
ously described [56]. Briefly, C666-1 (3×105) were seeded
in 6-well plates and treated for 48 hours with 1 μM
ATT13387 (the minimum concentration that had shown
maximum cell growth inhibition in MTT assay). Both
adherent cells and floating cells were collected for ana-
lysis. The cells were fixed in 70% cold ethanol, stained
with 1 mg/ml propidium iodide (PI) and analyzed by
FACSCalibur flow cytometer (Becton Dickinson, Franklin
Lakes, NJ). Fluorescence profiles represent the DNA
content of the PI stained cells.
Nucleus and SAHF staining with DAPI
DAPI nucleus staining was used to identify the apoptotic
cells with chromatin condensation and fragmentation
and/or senescence cells with senescence-associated het-
erochromatic foci (SAHFs) formation as previously de-
scribed [22,57]. For the apoptotic nucleus staining,
3×105 cells were seeded in 6-well plates and treated with
1 μM AT13387 for 48 hours. For the SAHF staining,
3×105 cells were seeded in 6-well plates and treated with
1 μM and 10 μM AT13387 for 96 hours. Both adherent
cells and floating cells were collected onto slides by
cytospin. The cells were fixed with 2% paraformaldehyde
and permeablized with 0.2% Triton-X. The cells were
then stained with DAPI (1 μg/ml) and the nuclear
images were captured under a fluorescence microscope
(ECLIPSE Ti, Nikon) equipped with camera. At least
200 cells were counted from different microscopic
fields.
Senescence-associated β-Galactosidase cell staining
Senescence-associated β-galactosidase (SA-β-gal) activa-
tion was detected by cytochemical staining with the X-Gal
according to the protocol of the Cell Signaling Senescence
β-Galactosidase Staining Kit #9860. Briefly, C666-1
(8×104) cells were seeded onto wells of a 24-well plate and
the cells were treated with 1 μM and 10 μM of AT13387for 72 hours. Both adherent cells and floating cells were
collected and stained with X-gal (pH6) overnight in the
dark. The senescent cells were stained with blue color.
Cells images were captured under microscope with a
camera.
Western blotting analysis
Western blotting analysis was performed as previously
described [56]. In brief, C666-1 cells (5×105) were
seeded onto the 6-well plate and the cells were treated
with 1 μM and 10 μM of AT13387 for 48 hours, 72 hours
and 96 hours. Both adherent cells and floating cells were
collected and lysed with ice-cold lysis buffer (250 mM
Tris–HCl, pH 8; 1% NP-40 and 150 mM NaCl contain-
ing 1% phosphatase inhibitors cocktail (Calbiochem, San
Diego, CA) and 0.25% protease inhibitors cocktail
(Sigma, St. Louis, MO). Samples were resolved on SDS–
polyacrylamide gel and transferred to PVDF membrane
(Millipore, Billerica, MA). The membrane was blocked
with 5% non-fat milk, incubated with primary antibodies
(1:1000) followed by corresponding secondary antibodies
(1:4000). A Western blotting substrate (Labfrontier Co.
Ltd., Bio Division) was added and chemiluminescence
signal was detected on the X-ray film. β-actin primary
antibody (1:4000) was probed and served as an internal
control.
siRNA knockdown
Knockdown with siRNA and transfection were per-
formed according to the manufacturer’s instruction. In
brief, C666-1 cells (5×105cells/well) were seeded onto
fibronectin-coated 35-mm dishes for 24 hours. Cells
were transfected with 5 nM of si-Skp2 RNA (a pool of 4
siRNA: GGAUGUGACUGGUCGGUUG; GGUAUCGC
CUAGCGUCUGA; UCGGUGCUAUGAUAUAAUA; UG
UCAAUACUCUCGCAAAA), or si-Control RNA (UGG
UUUACAUGUCGACUAA) (Dharmacon, Lafayette, CO)
using Lipofectamine Reagent 2000 (Invitrogen, Carlsbad,
CA). After 6 hours of transfection, the medium was then
replaced by fresh medium. Cells were harvested for
western-blotting analysis after 72 hours of transfection.
Migration assay
The migration capability of AT13387-treated C666-1
cells was analyzed using the transwell migration assay.
C666-1 cells (5×105) were seeded on the 6-well plate
and treated with 1 μM and 10 μM AT13387 for 72 hours.
Cells were then harvested and 2×105 viable cells were
seeded on the upper chamber of the transwell. After
24 hours of incubation, the cells that had migrated
through the membrane were fixed in 2% paraformalde-
hyde, permeablized with 0.2% Triton-X, and stained with
1 μg/ml DAPI. The stained cell images were captured
under fluorescence microscopy (ECLIPSE Ti, Nikon). At
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fields.
Tumor sphere formation assay
Tumor sphere formation assay was performed as previ-
ously described [32]. C666-1 cells were dissociated into
single cells and seeded in low cell density (2×103) on a
24-well ultra-low attachment plate (Corning, Acton,
MA), and cultured with serum-free DMEM/F-12
(Invitrogen, Carlsbad, CA), 20 ng/ml EGF (Sigma, St.
Louis, MO), 20 ng/ml bFGF (Cell Signaling, Danvers,
MA), and 20 ng/ml insulin (Cell Signaling, Danvers,
MA). The cultures were fed with fresh serum-free
DMEM/F12 supplemented with growth factors every
other day. For studying the effect of AT13387 on the
tumor sphere forming ability, AT13387 was added to the
culture on the same day of seeding the dissociated
C666-1 single cells. After 7-days of incubation, the im-
ages of cells were captured under an inverted micro-
scope equipped with camera. Tumor spheres having
diameter >20 μm were counted using Image J software.
Total numbers of tumor spheres formed in AT13387-
treated and-untreated cultures were compared. In order
to study the effect of AT13387 on the growth of estab-
lished tumor spheres, tumor spheres were first allowed
to grow for 7 days, followed by incubation with
AT13387 for further 7 days. Then the images of
AT13387-treated and– untreated tumor spheres were
captured under an inverted microscope equipped with
camera. Tumor spheres with diameter >20 μm were
measured and counted using Image J software. Data
from each treatment were presented as size distribu-
tion profile with mean diameter.
Immunofluorescence staining and FACS analysis of
spheroid cells
Tumor spheres for CD44 and SOX2 immunofluores-
cence staining and FACS analysis were established as de-
scribed above. Briefly, C666-1 cells were incubated in
serum-free DMEM/F12 supplemented with growth fac-
tors for 7 days to allow tumor sphere formation. Then,
AT13387 was added to the tumor spheres culture and
incubated in serum-free DMEM/F12 supplemented with
growth factors for another 7 days. For CD44 and SOX2
immunofluorescence staining, the tumor spheres were
carefully collected and fixed with 2% paraformaldehyde
and permeablized with 0.2% Triton-X. Tumor spheres
were then incubated with Alexa Fluor® 488 conjugated
CD44 and Alex Fluor® 647 conjugated SOX2 antibodies
in the dark. The immunofluorescence signals were visual-
ized and imaged using an Olympus Fluoview 1000 con-
focal scanning laser microscope. For FACS analysis,
tumor spheres were collected and the spheroid cells were
resuspended in PBS and fixed in 1.6% paraformaldehyde.Then the cells were pelleted and resuspended in ice-cold
methanol. The cells were washed twice in incubation
buffer [0.5% bovine serum albumin (BSA) in PBS],
and stained with Alexa Fluor® 488 conjugated CD44
and Alex Fluor® 647 conjugated SOX2 antibodies in
the dark. Respective mouse or rabbit IgG isotypic
controls were included as negative controls. For each
sample, 10,000 cells were acquired and analyzed by
FACSCalibur flow cytometer (Becton Dickinson, Franklin
Lakes, NJ).Nude mice tumorigenicity assay
Nude mice were supplied and housed by Laboratory
Animal Unit of the University of Hong Kong. Experi-
ments were conducted under license from the Hong
Kong Department of Health and approved by Commit-
tee on the Use of Live Animals in Teaching and
Research (CULTAR) at the University of Hong Kong.
AT13387 drug formulation used in a previous publica-
tion [14] was used in the nude mice tumorigenicity
assay. In brief, 1×107 C666-1 cells were subcutaneously
(s.c.) injected into the flank of 8-10 week old female
athymic BALB/c nu/nu mice. Immediately after cell in-
oculation, the mice were randomly divided into two
groups (three mice per group) for either treatment with
AT13387 or vehicle. For the drug treatment group,
AT13387 formulated in 17.5% hydroxy-propyl-β-cyclo-
dextrin in sterile water was administrated at 50 mg/kg
by intraperitoneal (i.p.) injection at a dose volume of
10 ml/kg twice per week (on Days 2 and 5 of each week).
For the control group, the drug vehicle alone was given
through i.p. injection. The tumor volume in mm3 (length ×
width × height) and the mice body weight were measured
weekly until tumor volume reached 1000 mm3.Statistical analysis
All results were representative results from at least two
independent experiments. Each data points with error
bars were the arithmetic mean ± SE of three replicates
(n = 3). The p-values were calculated using Student’s t-test,
p-value < 0.05 was considered as statistically significant.
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